March 11, 2022 01:45 PM EST
Law

Cal­i­for­nia stem cell clin­ic to pay out $3.65M set­tle­ment to for­mer pa­tients for in­ef­fec­tive treat­ments

Paul Schloesser

Associate Editor

Four years af­ter the FDA ad­mon­ished stem cell clin­ic Stem­Genex for mak­ing du­bi­ous claims about its ser­vices in treat­ing in­cur­able dis­eases, and 3 years af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times